Background Previous prognostic models for second-line systemic therapy in patients with
metastatic renal cell carcinoma have not been studied in the setting of targeted therapy. We …

Summary Background The International Metastatic Renal-Cell Carcinoma Database
Consortium model offers prognostic information for patients with metastatic renal-cell …

Background The use of third-line targeted therapy (TTT) in metastatic renal cell carcinoma
(mRCC) is not well characterized and varies due to the lack of robust data to guide treatment …

Background The advent of targeted therapies in the past 7 years has extended median
survival for metastatic renal-cell carcinoma. This improvement in clinical outcome has …

BACKGROUND. The majority of metastatic renal cell carcinoma (mRCC) clinical trials that
examined targeted agents used progression‐free survival (PFS) as the primary endpoint …

Purpose: To develop a single validated model for survival in metastatic renal cell carcinoma
(mRCC) using a comprehensive international database. Experimental Design: A …

Aim To evaluate the implementation of targeted therapy on overall survival (OS) in a
complete national cohort of patients with metastatic renal cell carcinoma (mRCC). Methods …

Background Targeted therapies in metastatic renal cell carcinoma (mRCC) have been
approved based on registration clinical trials that have strict eligibility criteria. The clinical …

In the US and Europe, clinical practice guidelines for metastatic renal cell carcinoma have
undergone several revisions as a result of the introduction of molecular‐targeted therapies …

The purpose of the study was to identify a comprehensive prognostic system of pretreatment
clinical parameters in 425 patients (pts) with metastatic renal-cell carcinoma treated with …